<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Entresto</title>
    <link rel="stylesheet" href="assets/css/bootstrap.min.css">
    <link rel="stylesheet" href="assets/css/style.css">


</head>

<body>


    <header id="header">
        <div class="header-top text-14">
            <div class="container text-center d-sm-flex align-items-center align-items-lg-start justify-content-between ">
                <a href="/" class="logo">
                    <img src="assets/images/logo.svg" alt="">
                </a>
                <div class="d-lg-flex mt-3">
                    <p class="text-color-primary mb-1 mb-lg-0">
                        For Canadian Healthcare Professionals
                    </p>
                    <div class="text-color-primary d-sm-flex align-items-start">
                        <a href="important-safety-information.html">
                            Important Safety Information
                        </a>
                        </a>
                        <a href="#">
                            Francais
                        </a>
                    </div>
                </div>
            </div>
        </div>
        <nav class="navbar navbar-expand-lg navbar-light bg-dark">
            <div class="container">
                <button class="navbar-toggler ms-auto" type="button" data-bs-toggle="collapse"
                    data-bs-target="#navbarSupportedContent" aria-controls="navbarSupportedContent"
                    aria-expanded="false" aria-label="Toggle navigation">
                    <span class="navbar-toggler-icon">
                        <svg viewBox="0 0 24 24" fill="#fff">
                            <path d="M3 18h18v-2H3v2zm0-5h18v-2H3v2zm0-7v2h18V6H3z"></path>
                        </svg>
                    </span>
                </button>
                <div class="collapse navbar-collapse" id="navbarSupportedContent">
                    <ul class="navbar-nav">
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-efficacy.html">
                                Efficacy Data
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-safety-profile.html">
                                Safety Profile
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-dosing.html">
                                Dosing
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-moa.html">
                                Mechanism of Action
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="hf-guidelines.html">
                                Guidelines
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-resources.html">
                                Resources
                            </a>
                        </li>
                    </ul>
                </div>
            </div>
        </nav>
        <div class="header-bottom"></div>
    </header>

    <section class="page-content isi">
        <div class="container">
            <h2 class="common-title-1">
                Important safety information
            </h2>
            <div class="common-block">
                <h4>
                    Clinical use:

                </h4>
                <ul>
                    <li>
                        <span>•</span>
                        <p>
                            ENTRESTO<sup>®</sup> should be administered in combination with other heart
                            failure
                            therapies, in place of an ACEi or ARB.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            ENTRESTO<sup>®</sup> should be initiated, and up-titration conducted, by a
                            physician
                            experienced with the treatment of heart failure.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            No dosage adjustment is required in patients over 65 years. However, ENTRESTO<sup>®</sup>
                            has been studied in
                            a limited number of patients above the age of
                            80 years. Caution is required in these patients.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            The safety and efficacy of ENTRESTO<sup>®</sup> in pediatric patients (&lt;18 years of age)
                            has not been established.
                        </p>
                    </li>
                </ul>
            </div>
            <div class="common-block">
                <h4>
                    Contraindications:
                </h4>
                <ul>
                    <li>
                        <span>•</span>
                        <p>
                            Recent symptomatic hypotension prior to initiation of treatment with ENTRESTO<sup>®</sup>
                            (sacubitril/valsartan)
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Concomitant use with any drug formulation containing an ACEi, due to potential enhanced risk
                            of angioedema. <strong>ENTRESTO<sup>®</sup> must not be administered until at least 36 hours
                                have elapsed following discontinuation of ACEi therapy.</strong>
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Known history of angioedema related to previous ACEi or ARB therapy
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            History of hereditary or idiopathic angioedema
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            As for any formulation containing an ACEi or ARB, use of ENTRESTO<sup>®</sup> together with
                            aliskiren-containing
                            drugs is contraindicated in patients with diabetes mellitus, whether Type 1 or 2, or in
                            patients with moderate to severe renal impairment, i.e.,
                            eGFR &lt;60 mL/min/1.73 m<sup>2</sup>. </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Pregnant and nursing women
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Hypersensitivity to the active substances,
                            sacubitril or valsartan, or to any of the excipients
                        </p>
                    </li>
                </ul>



            </div>
            <div class="common-block">
                <h4>
                    Most serious warnings and precautions:
                </h4>
                <p>
                    <strong>
                        Use in pregnancy:
                    </strong>
                    When used in pregnancy, ARBs can cause injury to or even death of the developing fetus. When
                    pregnancy is detected, ENTRESTO<sup>®</sup> should be discontinued as soon as possible.
                </p>
            </div>
            <div class="common-block">
                <p>
                    <strong>Use of ACEi:</strong> ENTRESTO<sup>®</sup> must not be initiated until at least 36 hours
                    have elapsed following discontinuation of ACEi therapy due to the risk of angioedema. If treatment
                    with ENTRESTO<sup>®</sup> is stopped, ACEi therapy must not be initiated until 36 hours after the
                    last dose of ENTRESTO<sup>®</sup>.
                </p>
            </div>
            <div class="common-block">
                <p>
                    <strong>NT-proBNP monitoring:</strong> Due to the action of sacubitril on BNP levels, only NT-proBNP
                    may be a
                    suitable biomarker for the monitoring of heart failure patients treated with ENTRESTO<sup>®</sup>.
                </p>
            </div>
            <div class="common-block">
                <p>
                    <strong>Use of medications known to raise serum potassium levels:</strong>
                    Caution should be exercised when co-administering ENTRESTO<sup>®</sup> with medications known to
                    raise serum potassium levels (e.g., potassium-sparing diuretics, potassium supplements).
                </p>
            </div>
            <div class="common-block">
                <h4>
                    Other relevant warnings and precautions:
                </h4>
                <ul>
                    <li>
                        <span>•</span>
                        <p>
                            ENTRESTO<sup>®</sup> should not be administered with any other drug formulation containing
                            an ARB.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Caution when co-administering ENTRESTO<sup>®</sup> with direct renin inhibitors such as
                            aliskiren.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Angioedema: Caution is recommended in patients with a prior history of any angioedema and in
                            black patients.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Symptomatic hypotension: ENTRESTO<sup>®</sup> is not recommended in patients with systolic
                            blood pressure &lt;100 mmHg at the time of treatment initiation.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Hyperkalemia: Measure serum potassium before instituting ENTRESTO<sup>®</sup>, and during
                            treatment, as appropriate, taking into account the patient’s
                            predisposition to develop hyperkalemia. <br>
                            Patients with serum potassium &gt;5.2 mmol/L prior to initiation of treatment with
                            ENTRESTO<sup>®</sup> have not been studied. Careful monitoring of serum
                            potassium is recommended in patients with severe renal impairment, diabetes mellitus,
                            hypoaldosteronism, or a high potassium intake in their diet.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Decreases in renal function in susceptible individuals. Closely monitor serum creatinine,
                            and
                            down-titrate or interrupt ENTRESTO<sup>®</sup> in patients who
                            develop a clinically significant decrease in renal function. Before initiation of therapy
                            and during
                            treatment, assess renal function, as appropriate.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Caution in patients with renal artery stenosis, if ENTRESTO<sup>®</sup> is to be used.
                            Careful
                            monitoring of renal function should be carried out.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Advising women of child-bearing potential to use contraception during treatment with
                            ENTRESTO<sup>®</sup> and for one (1) week after their last dose.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            Nursing women: Because of the potential risk for adverse drug reactions in breastfed
                            newborns, a
                            decision should be made whether to abstain from
                            breast-feeding or to discontinue ENTRESTO<sup>®</sup> while breast-feeding, taking into
                            account the
                            importance of ENTRESTO<sup>®</sup> to the mother.
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            A starting dose of 24 mg sacubitril/26 mg valsartan twice daily is recommended in patients
                            with
                            moderate hepatic impairment (Child-Pugh B). <br>
                            ENTRESTO<sup>®</sup> is not recommended in patients with severe hepatic impairment
                            (Child-Pugh C).
                        </p>
                    </li>
                    <li>
                        <span>•</span>
                        <p>
                            ENTRESTO<sup>®</sup> is not recommended in patients with severe renal impairment (eGFR
                            &lt;30
                            mL/min/1.73 m<sup>2</sup>).
                        </p>
                    </li>
                </ul>





            </div>
            <div class="common-block">
                <h4>
                    For more information:
                </h4>
                <p>
                    Please consult the Product Monograph at <a
                        href="https://www.novartis.ca/EntrestoMonograph">www.novartis.ca/EntrestoMonograph</a> for
                    important information
                    relating to adverse reactions, drug interactions, and dosing information which have not been
                    discussed in this piece. The Product Monograph is also available by calling 1-800-363-8883 or via
                    medinfo.canada@novartis.com.
                </p>
            </div>

            <div class="common-block reference-block">
                <h4>
                    References:
                </h4>
                <ul>
                    <li>
                        <span>
                            1.
                        </span>
                        <p>
                            ENTRESTO<sup>®</sup> Product Monograph. Novartis Pharmaceuticals Canada Inc. July 13, 2021.
                        </p>
                    </li>
                    <li>
                        <span>
                            2.
                        </span>
                        <p>
                            Novartis Data on File – First and only. 2021.
                        </p>
                    </li>
                    <li>
                        <span>
                            3.
                        </span>
                        <p>
                            McDonald M, et al. CCS/CHFS Heart Failure Guidelines Update: Defining a new pharmacologic
                            standard of
                            care for heart failure with reduced ejection fraction. Can J Cardiol
                            2021;37(4):531-546.
                        </p>
                    </li>
                    <li>
                        <span>
                            4.
                        </span>
                        <p>
                            McMurray JJ, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N
                            Engl J Med
                            2014;371:993-1004.
                        </p>
                    </li>
                    <li>
                        <span>
                            5.
                        </span>
                        <p>
                            Novartis Data on File – PARADIGM. 2020.
                        </p>
                    </li>
                    <li>
                        <span>
                            6.
                        </span>
                        <p>
                            Packer M, McMurray JJ, Desai AS et al. Angiotensin receptor neprilysin inhibition compared
                            with
                            enalapril on the risk of clinical progression in surviving patients with heart failure.
                            Circulation 2015;131:54-61.
                        </p>
                    </li>
                    <li>
                        <span>
                            7.
                        </span>
                        <p>
                            Desai AS, McMurray JJ, Packer M et al. Effect of the angiotensin-receptor-neprilysin
                            inhibitor LCZ696
                            compared with enalapril on mode of death in heart failure patients. Eur Heart
                            J 2015;36(30):1990-7.
                        </p>
                    </li>
                    <li>
                        <span>
                            8.
                        </span>
                        <p>
                            Volpe M, et al. The natriuretic peptides system in the pathophysiology of heart failure:
                            From the molecular basis to treatment. <i>Clin Sci</i> (Lond). 2016;130(2):57-77.
                        </p>
                    </li>
                    <li>
                        <span>
                            9.
                        </span>
                        <p>
                            Fielitz J, et al. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve
                            stenosisand heart failure. Circulation. 2002;105:286-289.
                        </p>
                    </li>




                </ul>









            </div>

        </div>
    </section>

    <footer>
        <div class="container">
            <div class="links text-center text-lg-start mb-4 mb-lg-0">
                <a href="privacy-policy.html">
                    Privacy Policy
                </a>
                |
                <a href="terms-of-use.html">
                    Terms of Use
                </a>
                | <a href="#">
                    Cookie Settings
                </a>
            </div>
            <div class="d-flex align-items-lg-end flex-column flex-lg-row">
                <a href="#">
                    <img src="assets/images/footer-logo.svg" alt="">
                </a>
                <p class="mt-3 mt-lg-0">
                    Entresto is a registered trademark. <br>
                    © Novartis Pharmaceuticals Canada Inc. 2022
                </p>
                <div class="footer-right mt-2 mt-lg-0">
                    <p class="mb-3 mb-lg-0">
                        187298E - July 2022
                    </p>
                    <img src="assets/images/footer-img-2.svg" alt="">
                    <img src="assets/images/footer-img-3.svg" alt="">
                </div>
            </div>
        </div>
    </footer>

    <script src="assets/js/jquery.js"></script>
    <script src="assets/js/bootstrap.bundle.min.js"></script>
    <script src="assets/js/index.js"></script>
</body>

</html>